Aptose Biosciences (TSE:APS) Reaches New 12-Month Low at $1.85

Aptose Biosciences Inc. (TSE:APS) (NASDAQ:APTO)’s share price reached a new 52-week low on Monday . The stock traded as low as C$1.85 and last traded at C$1.84, with a volume of 13836 shares changing hands. The stock had previously closed at C$1.90.

Aptose Biosciences Stock Performance

The stock has a market capitalization of C$27.34 million, a P/E ratio of -0.17 and a beta of 1.44. The company’s fifty day simple moving average is C$2.24 and its two-hundred day simple moving average is C$2.95. The company has a debt-to-equity ratio of 14.27, a quick ratio of 5.41 and a current ratio of 0.78.

Aptose Biosciences (TSE:APS) (NASDAQ:APTO) last announced its earnings results on Tuesday, March 26th. The biotechnology company reported C($1.96) earnings per share for the quarter, topping analysts’ consensus estimates of C($1.98) by C$0.02. As a group, equities analysts forecast that Aptose Biosciences Inc. will post -0.59 EPS for the current year.

Aptose Biosciences Company Profile

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.